IART · Integra LifeSciences Holdings Corporation

Current Thesis

Integra LifeSciences' turnaround requires a recovery above the former $17 market shelf and delivery of the SurgiMend relaunch management still expects in Q4 2026; a weekly close below $15.50 would end the prospective repair case. The earlier re-rating thesis already failed: the published record identifies weekly closes of $16.74 on 2026-08-21 and $16.89 on 2026-08-28 beneath its $17 boundary. The narrative is dead in that earlier leg — the supplied 2026-09-11 adjusted close of $15.50 shows the shelf remains unrecovered.

The update since August is substantive. Integra furnished a lender presentation on 2026-09-08 in connection with planned refinancing of its senior credit facility, and its calendar now lists a 2026-09-15 healthcare conference. These disclosures replace the earlier absence-of-events framing, but neither establishes completed refinancing or operating recovery. September 8 Form 8-K, company events calendar.

Bullish and bearish views on Integra LifeSciences Holdings Corporation

The model's bull view on Integra LifeSciences Holdings Corporation (IART), in brief: Manufacturing milestones remain explicit. The bear view: Demand recovery remains limited. The 2026-07-29 results reported Q2 organic revenue growth of 0.7%. That observation does not establish an accelerating recovery; the available quarterly sample is too small to support a durable growth claim. Q2 earnings release. Reported revenue… Both cases follow in full.

Bull Case

• Manufacturing milestones remain explicit. Management's 2026-09-08 presentation says Braintree became operational in Q2 2026 and commercial revenue remains expected in Q4 2026, alongside the SurgiMend relaunch. These are management expectations; failure to deliver by the end of that quarter would contradict the operational recovery case. September investor presentation.
• Earnings guidance survived July. The 2026-07-29 release reaffirmed full-year adjusted earnings per share (EPS) guidance of $2.40–$2.50 and organic revenue growth guidance of 0.8%–3.3%. This supports an earnings-stabilization hypothesis, which a subsequent reduction in that EPS range would invalidate. Q2 earnings release.

Bear Case

• Demand recovery remains limited. The 2026-07-29 results reported Q2 organic revenue growth of 0.7%. That observation does not establish an accelerating recovery; the available quarterly sample is too small to support a durable growth claim. Q2 earnings release.
• Reported revenue guidance fell. On 2026-07-29, Integra lowered its full-year revenue range to $1.654 billion–$1.695 billion, attributing the change to currency effects. The retained EPS range therefore did not accompany an increase in the revenue outlook. Q2 earnings release.
• Remediation remains unfinished work. The 2026-09-08 presentation describes warning-letter commitments as on track for completion during 2026. That is a management timetable, not confirmation that the Food and Drug Administration has closed the warning letter. September investor presentation.

Setup & Price Structure

The supplied adjusted daily-bar series records a $15.50 close on 2026-09-11, a three-month price decline of 12.8%, and a price 21.9% below its $19.85 trailing annual high. Its 14-period relative strength index (RSI) was 27.0 on that date. These are measured weakness indicators; they do not demonstrate a reversal.

The prospective repair test uses $15.50 strictly as the 2026-09-11 reference close, not as an established support shelf. A weekly close above the former $17 shelf would establish the price component of recovery; a weekly close below $15.50 first would invalidate this narrower case. The historical $17 breach remains a completed failure of the earlier thesis.

Attention has a dated cluster: the company calendar lists Wells Fargo on 2026-09-09 and Morgan Stanley on 2026-09-15. Conference appearances establish investor-relations activity, not expanding ownership or inflows. Current retail-flow, short-interest and moving-average measurements are missing, so the evidence does not support a crowding verdict. Company events calendar.

Catalyst Calendar (next 30 days)

• 2026-12-31 — End of management's Q4 delivery window. This is the deadline implied by the quarter, not an announced launch day. The 2026-09-08 presentation expects the SurgiMend relaunch and Braintree commercial revenue during Q4 2026; a disclosed delay beyond that window would break the operational leg. September investor presentation.

Elapsed catalysts

• 2026-09-15 — Morgan Stanley healthcare conference. The company schedules its presentation for 4:05 p.m. Eastern time. The observable test is whether management changes its manufacturing or financing timetable; the scheduled appearance alone does not resolve either issue. Company events calendar. (passed 5d ago)

What Would Change Our Mind

Failure to stabilize around the September reference close would end the prospective repair case: a weekly close below $15.50 is the observable price condition. Conversely, a weekly close above the former $17 shelf, followed by company-confirmed SurgiMend relaunch and Braintree commercial revenue within Q4 2026, would satisfy its price and operating tests. Until those observations arrive, management's 2026-09-08 timetable remains a forecast rather than demonstrated recovery.

Correlation Notes

This is a single-company turnaround case; no measured peer-return series supports a sector-correlation claim as of 2026-09-11. Currency exposure is evidenced by the revenue-guidance reduction attributed to exchange rates on 2026-07-29, while financing exposure is evidenced by the refinancing presentation furnished on 2026-09-08. Neither disclosure establishes the shares' sensitivity to a dollar index or interest-rate move. Q2 earnings release, September 8 Form 8-K.